The National Institute for Health and Care Excellence (NICE) has issued new guidance recommending the use of specific hybrid closed-loop systems, often referred to as an 'artificial pancreas', for pregnant women living with type 1 diabetes. This significant recommendation aims to offer a more precise and automated method of managing blood glucose levels during pregnancy, a critical period where tight control is essential for maternal and foetal health.
A hybrid closed-loop system works by continuously monitoring glucose levels in the body and automatically adjusting insulin delivery via a pump. This technology helps to maintain blood sugar within a target range, reducing the frequency of both dangerously high (hyperglycaemia) and dangerously low (hypoglycaemia) blood glucose episodes. For pregnant women with type 1 diabetes, maintaining stable blood sugar is particularly challenging due to hormonal changes and the increased metabolic demands of pregnancy.
The implications of this recommendation are substantial for the estimated 1,500 pregnant women with type 1 diabetes in England and Wales each year. Poorly controlled diabetes during pregnancy can lead to a range of complications, including pre-eclampsia, premature birth, larger-than-average babies (macrosomia), and an increased risk of birth defects. By providing a more effective tool for glucose management, the new guidance seeks to mitigate these risks, leading to healthier outcomes for both mother and child.
While the technology represents a significant advancement, its implementation across the NHS will require careful planning. Healthcare professionals will need training to support patients in using these complex devices, and patients themselves will require education on how to integrate the system into their daily lives. The initial cost of these systems, though potentially offset by reduced complication rates and associated healthcare expenditure in the long term, will also be a factor in their rollout.
NICE's decision follows a comprehensive review of clinical evidence, which demonstrated the efficacy and safety of these systems in improving glycaemic control in this specific patient group. The recommendation underscores a commitment to leveraging advanced medical technology to enhance care for vulnerable populations within the NHS. This move brings the UK in line with other countries that have already begun to adopt similar technologies for diabetes management.
Patients currently managing type 1 diabetes during pregnancy are advised to discuss this new guidance with their diabetes care team or GP to understand if a hybrid closed-loop system might be suitable for their individual circumstances. The full implementation of this guidance is expected to be a phased approach across different NHS trusts.